27 related articles for article (PubMed ID: 38560204)
1. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of Atypical Cadherin FAT1 Promotes an Immunosuppressive Tumor Microenvironment
Irshad K; Srivastava C; Malik N; Arora M; Gupta Y; Goswami S; Sarkar C; Suri V; Mahajan S; Gupta DK; Suri A; Chattopadhyay P; Sinha S; Chosdol K
Front Immunol; 2022; 13():813888. PubMed ID: 35720420
[TBL] [Abstract][Full Text] [Related]
3. Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations.
Zhang W; Tang Y; Guo Y; Kong Y; Shi F; Sheng C; Wang S; Wang Q
NPJ Precis Oncol; 2022 Jun; 6(1):46. PubMed ID: 35739249
[TBL] [Abstract][Full Text] [Related]
4. Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer.
Zhu G; Ren D; Lei X; Shi R; Zhu S; Zhou N; Zu L; Mello RA; Chen J; Xu S
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808631
[TBL] [Abstract][Full Text] [Related]
5. [Expression of FAT1 in Lung Adenocarcinoma and Its Relationship
with Immune Cell Infiltration].
Ding C; Zhao W; Huang H; Li Y; Zhang Z; Zhang R; Wang Y; Wu D; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2024 Feb; 27(2):109-117. PubMed ID: 38453442
[TBL] [Abstract][Full Text] [Related]
6.
Chen C; Li Y; Liu H; Liao M; Yang J; Liu J
Heliyon; 2024 Apr; 10(7):e28356. PubMed ID: 38560204
[TBL] [Abstract][Full Text] [Related]
7. The diverse functions of FAT1 in cancer progression: good, bad, or ugly?
Chen ZG; Saba NF; Teng Y
J Exp Clin Cancer Res; 2022 Aug; 41(1):248. PubMed ID: 35965328
[TBL] [Abstract][Full Text] [Related]
8. Unveiling the role of KRAS in tumor immune microenvironment.
Xu M; Zhao X; Wen T; Qu X
Biomed Pharmacother; 2024 Feb; 171():116058. PubMed ID: 38171240
[TBL] [Abstract][Full Text] [Related]
9. Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer.
Wu W; Wang X; Le W; Lu C; Li H; Zhu Y; Chen X; An W; Xu C; Wu Q; Wang L
Front Immunol; 2022; 13():1001297. PubMed ID: 36700224
[TBL] [Abstract][Full Text] [Related]
10. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy.
Rouzbahani E; Majidpoor J; Najafi S; Mortezaee K
Biomed Pharmacother; 2022 Dec; 156():113906. PubMed ID: 36306594
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
12. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.
Peters S; Paz-Ares L; Herbst RS; Reck M
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858709
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
